Table 1.
Renal denervation group (n = 30) | Control group (n = 30) | P | |
---|---|---|---|
Age [years] | 59.0 (12.1) | 61.3 (11.1) | 0.446 |
Sex [male] | 25 (83.3%) | 22 (73%) | 0.347 |
Body mass index [kg/m2] | 26.8 (2.6) | 26.7 (2.8) | 0.939 |
Medical history: | |||
Hypertension | 21 (70.0%) | 18 (60.0%) | 0.417 |
Coronary heart disease | 17 (56.7%) | 18 (60.0%) | 0.793 |
Atrial fibrillation | 4 (13.3%) | 3 (10.0%) | 0.688 |
Type 2 diabetes | 8 (26.7%) | 7 (23.3%) | 0.766 |
Patients receiving drug class: | |||
ACE or ARB | 29 (96.7%) | 28 (93.3%) | 1.000 |
Beta-blockers | 23 (76.7%) | 24 (80.0%) | 0.754 |
Aldosterone antagonists | 6 (20.0%) | 4 (13.3%) | 0.488 |
Calcium-channel blockers | 14 (46.7%) | 12 (40.0%) | 0.602 |
Digoxin | 3 (10%) | 1 (3.3%) | 0.612 |
Loop diuretics | 14 (46.7%) | 16 (53.3%) | 0.606 |
Hemoglobin | 119.1 (25.9) | 112.3 (24.5) | 0.299 |
Efficacy endpoint: | |||
NT-proBNP [pg/mL] | 797.7 (356.1) | 784.7 (377.1) | 0.892 |
Six minute walk test [m] | 217.5 (69.5) | 210.0 (63.0) | 0.666 |
NYHA class: | |||
Class II | 17 (56.7%) | 16 (53.3%) | 0.795 |
Class III | 13 (43.3%) | 14 (46.7%) | 0.795 |
Echocardiographic LVEF [%] | 35.0 (3.2) | 34.8 (3.2) | 0.872 |
Safety endpoint: | |||
GFR [mL/min/1.73 m2] | 104.8 (35.9) | 96.4 (31.8) | 0.337 |
Symbolic BP [mmHg] | 142.0 (24.8) | 143.2 (20.7) | 0.844 |
Diastolic BP [mmHg] | 79.8 (12.6) | 81.7 (12.9) | 0.579 |
Heart rate [bpm] | 68.7 (7.9) | 69.4 (6.9) | 0.728 |
Data are mean (standard deviation) or number (%). ACE — angiotensin-converting enzyme inhibitor; ARB — angiotensin II receptor blocker; BP — blood pressure; GFR — glomerular filtration rate; LVEF — left ventricular ejection fraction; NT-proBNP — N-terminal pro-B-type natriuretic peptide; NYHA — New York Heart Association